#STOCKFUTURESTIPS
Aurobindo Pharma gains after good
Q1 outcome
The company's robust product portfolio is spread
over 7 major therapeutic/product areas encompassing antibiotics,
anti-retrovirals, CVS, CNS, gastroenterologicals, anti-allergies and
anti-diabetics, supported by an outstanding R&D set-up. The company is
marketing these products globally, in over 150 countries. FOR MORE DETAILS CALL
@ 8015672177 www.intradaystockfutures.com
This comment has been removed by the author.
ReplyDelete